Markus Trunzer
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Mass Spectrometry Techniques and Applications, Analytical Chemistry and Chromatography, Pharmacogenetics and Drug Metabolism, Metabolomics and Mass Spectrometry Studies, Computational Drug Discovery Methods
Most-Cited Works
- → Metabolic Soft Spot Identification and Compound Optimization in Early Discovery Phases Using MetaSite and LC-MS/MS Validation(2008)116 cited
- → CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs(2011)90 cited
- → Multispecies Machine Learning Predictions of In Vitro Intrinsic Clearance with Uncertainty Quantification Analyses(2022)35 cited
- → NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo(2024)28 cited
- → Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome(2024)26 cited
- → An Integrated Approach for Identification and Target Validation of Antifungal Compounds Active against Erg11p(2012)25 cited
- → Two‐dimensional liquid chromatography/mass spectrometry set‐up for structural elucidation of metabolites in complex biological matrices(2007)15 cited
- → Comparison of a two‐dimensional liquid chromatography/mass spectrometry approach with a chip‐based nanoelectrospray device for structural elucidation of metabolites in a human ADME study using a quadrupole time‐of‐flight mass spectrometer(2007)13 cited
- → Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition(2024)13 cited
- → Evaluation of relative MS response factors of drug metabolites for semi‐quantitative assessment of chemical liabilities in drug discovery(2017)12 cited